Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines

Gastroenterology

Volumn 123, Issue 4, 2002, Pages 1191-1204

  Adachi, Yasushi ^a   Lee, Choon Taek ^b   Coffee, Keith ^a   Yamagata, Noboru ^a   Ohm, Joyce E ^a   Park, Kyung Ho ^b   Dikov, Mikhail M ^a   Nadaf, Sorena R ^a   Arteaga, Carlos L ^a   Carbone, David P ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; PROTEIN AKT1; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; TETRACYCLINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BYSTANDER EFFECT; CARCINOGENESIS; COLON CANCER; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFICACY; GENE THERAPY; HEAT; HUMAN; HUMAN CELL; LUNG CANCER; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; STARVATION; STRESS; VIRUS RECOMBINANT; XENOGRAFT;

EID: 0036787432     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.36023     Document Type: Article

References (55)

1. Baserga R. Oncogenes and the strategy of growth factors. Cell 1994;79:927-930.
2. Sara V, Hall K. Insulin-like growth factors and their binding proteins. Physiol Rev 1990;70:591-614.
3. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986;5:2503-2512.
4. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92:1472-1489.
5. Baserga R. The IGF-I receptor in cancer research. Exp Cell Res 1999;253:1-6.
6. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 1995;55:249-252.
7. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A 1993;90:11217-11221.
8. Trojan J, Blossey BK, Johnson TR, Rudin SD, Tykocinski M, Ilan J, Ilan J. Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc Natl Acad Sci U S A 1992;89:4874-4878.
9. Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, Ilan J. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 1993;259:94-97.
10. Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R, Rubin R. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-I) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 1994;54: 2218-2222.
11. Long L, Rubin R, Baserga R, Brodt P. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res 1995; 55:1006-1009.
12. Lee C-T, Wu S, Gabrilovich D, Chen H, Nadaf-Rahrov S, Ciernik IF, Carbone DP. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor 1 receptor on human lung cancer cell lines. Cancer Res 1996;56:3038-3041.
13. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993;75:59-72.
14. Lahm H, Amstad P, Wyniger J, Yilmaz A, Fischer JR, Schreyer M, Givel JC. Blockade of the insulin-like growth-factor-I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-II-mediated autocrine loop. Int J Cancer 1994;58: 452-459.
15. Remacle-Bonnet MM, Garrouste F, el Atiq F., Roccabianca M, Marvaldi J, Pommier G. des-(1-3)-IGF-I, an insulin-like growth factor analog used to mimic a potential IGF-II autocrine loop, promotes the differentiation of human colon-carcinoma cells. Int J Cancer 1992;52:910-917.
16. Remacle-Bonnet MM, Garrouste FL, Pommier GJ. Surface-bound plasmin induces selective proteolysis of insulin-like-growth-factor (IGF)-binding protein-4 (IGFBP-4) and promotes autocrine IGF-II bio-availability in human colon-carcinoma cells. Int J Cancer 1997;72:835-843.
17. Lahm H, Suardet L, Laurent PL, Fischer JR, Ceyhan A, Givel JC, Odartchenko N. Growth regulation and co-stimulation of human colorectal cancer cell lines by insulin-like growth factor I, II and transforming growth factor alpha. Br J Cancer 1992;65:341-346.
18. Simmons JG, Pucilowska JB, Lund PK. Autocrine and paracrine actions of intestinal fibroblast-derived insulin-like growth factors. Am J Physiol 1999;276:G817-G827.
19. Freier S, Weiss O, Eran M, Flyvbjerg A, Dahan R, Nephesh I, Safra T, Shiloni E, Raz I. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut 1999; 44:704-708.
20. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-625.
21. Manousos O, Souglakos J, Bosetti C, Tzonou A, Chatzidakis V, Trichopoulos D, Adami HO, Mantzoros C. IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 1999;83:15-17.
22. Resnicoff M, Burgaud JL, Rotman HL, Abraham D, Baserga R. Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res 1995;55:3739- 3741.
23. Prager D, Li HL, Asa S, Melmed S. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci U S A 1994;91:2181-2185.
24. Li S, Resnicoff M, Baserga R. Effect of mutations at serines 1280-1283 on the mitogenic and transforming activities of the insulin-like growth factor I receptor. J Biol Chem 1996;271: 12254-12260.
25. Burgaud JL, Resnicoff M, Baserga R. Mutant IGF-I receptors as dominant negatives for growth and transformation. Biochem Biophys Res Commun 1995;214:475-481.
26. D'Ambrosio C, Ferber A, Resnicoff M, Baserga R. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res 1996; 56:4013-4020.
27. Dunn SE, Ehrlich M, Sharp NJ, Reiss K, Solomon G, Hawkins R, Baserga R, Barrett JC. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 1998;58:3353-3361.
28. Jiang Y, Rom WN, Yie T-A, Chi CX, Tchou-Wong K-M. Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor. Oncogene 1999;18:6071-6077.
29. Reiss K, D'Ambrosio C, Tu X, Tu C, Baserga R. Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect. Clin Cancer Res 1998; 4:2647-2655.
30. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 1992;89:5547-5551.
31. Becker TC, Noel RJ, Coats WS, Gomez-Foix AM, Alam T, Gerard RD, Newgaard CB. Use of recombinant adenovirus for metabolic engineering of mammalian cells. In: Roth MG, ed. Protein expression in animal cells: methods in cell biology. Volume 43. New York: Academic, 1994:161-188.
32. Kotani K, Ogawa W, Hino Y, Kitamura T, Ueno H, Sano W, Sutherland C, Granner DK, Kasuga M. Dominant negative forms of Akt (protein kinase B) and atypical protein kinase C lambda do not prevent insulin inhibition of phosphoenolpyruvate carboxykinase gene transcription. J Biol Chem 1999;274:21305-21312.
33. Adachi Y, Yamamoto H, Itoh F, Hinoda Y, Okada Y, Imai K. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut 1999;45:252-258.
34. Chen HL, Gabrilovich D, Tampe R, Girgis KR, Nadaf S, Carbone DP. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet 1996;13:210-213.
35. Sell C, Baserga R, Rubin R. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res 1995;55:303-306.
36. Geier A, Beery R, Haimsohn M, Karasik A. Insulin-like growth factor-1 inhibits cell death induced by anticancer drugs in the MCF-7 cells: involvement of growth factors in drug resistance. Cancer Invest 1995;13:480-486.
37. Baserga R, Rubin R. Cell cycle and growth control. Crit Rev Eukaryot Gene Expr 1993;3:47-61.
38. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279:563-566.
39. Hankinson SE, Willett WE, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351;1393-1396.
40. Dunn SE, Torres JV, Nihei N, Barrett JC. The insulin-like growth factor-1 elevates urokinase-type plasminogen activator-1 in human breast cancer cells: a new avenue for breast cancer therapy. Mol Carcinog 2000;27:10-17.
41. Quinn KA, Treston AM, Unsworth EJ, Miller M-J, Vos M, Grimley C, Battey J, Mulshine JL, Cuttitta F. Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 1996;271:11477-11483.
42. Remacle-Bonnet MM, Culouscou JM, Garrouste FL, Rabenandrasana C, Marvaldi JL, Pommier GJ. Expression of type I, but not type II insulin-like growth factor receptor on both undifferentiated and differentiated HT29 human colon carcinoma cell line. J Clin Endocrinol Metab 1992;75:609-616.
43. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer Inst 1997;89:783-789.
44. Sharma R, Adam E, Schumacher U. The action of 5-fluorouracil on human HT29 colon cancer cells grown in SCID mice: mitosis, apoptosis and cell differentiation. Br J Cancer 1997;76:1011-1016.
45. Rodrigues NR, Rowan A, Smith MEF, Kerr IB, Bodmer WF, Gannon JV, Lane DP. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A 1990;87:7555-7559.
46. Meueller H, Eppenberger U. The dual role of p53 protein in chemosensitivity of human cancer. Anticancer Res 1996;16: 3845-3848.
47. Werner H, Karnieli E, Rauscher FJ, LeRoith D. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci U S A 1996; 93:8318-8323.
48. Licato LL, Keku TO, Wurzelmann JI, Murray SC, Woosley JT, Sandler RS, Brenner DA. In vivo activation of mitogen-activated protein kinases in rat intestinal neoplasia. Gastroenterology 1997;113:1589-1598.
49. Fantini J, Abadie B, Tirard A, Remy L, Ripert JP, el Battari A, Marvaldi J. Spontaneous and induced dome formation by two clonal cell populations derived from a human adenocarcinoma cell line, HT29. J Cell Sci 1986;83:235-249.
50. Remacle-Bonnet MM, Garrouste FL, Heller S, Andre F, Marvaldi JL, Pommier GJ. Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Res 2000;60:2007-2017.
51. Kulik G, Weber MJ. Akt-dependent and-independent survival signaling pathways utilized by insulin-like growth factor I. Mol Cell Biol 1998;18:6711-6718.
52. Datta SR, Brunet A, Greenberg ME, Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-2927.
53. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, Calabretta B, Baserga R. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 1999;19:7203-7215.
54. Burtscher I, Compagni A, Lamm GM, Christofori G. An insulin-like growth factor-mediated, phosphatidylinositol 3′ kinase-independent survival signaling pathway in beta tumor cells. Cancer Res 1999;59:3923-3926.
55. Pons S, Torres-Ateman I. IGF-I stimulates dephosphorylation of IkB through the serine phosphatase calcineurin (PP2B). J Biol Chem 2000;275:38620-38625.